NCT00794898View on ClinicalTrials.gov

Efficacy of Remicade in the Treatment of Active Rheumatoid Arthritis Despite Methotrexate (Study P03027)

PHASE4CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

July 1, 2003

Primary Completion Date

April 1, 2004

Study Completion Date

April 1, 2004

Conditions
Arthritis, Rheumatoid
Interventions
BIOLOGICAL

Infliximab (Remicade)

Infliximab 3 mg/kg infusions at Weeks 0, 2, and 6. All patients will continue to receive the same dose of MTX they were receiving at entry throughout the subsequent treatment period.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00794898 - Efficacy of Remicade in the Treatment of Active Rheumatoid Arthritis Despite Methotrexate (Study P03027) | Biotech Hunter | Biotech Hunter